Clinical Trial Update: Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update reports completion and posted results for ADXS-503 with or without pembrolizumab in metastatic non-small cell lung cancer (Phase 1/2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Squamous Cell Carcinoma of the Lung

Drugs mentioned

• ADXS-503
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Advaxis, Inc. | Conditions: Lung Cancer, Non-Small Cell, Metastatic Squamous Cell Carcinoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-06-04